Hikma Pharmaceuticals PLC : Still well oriented
Entry price | Target | Stop-loss | Potential |
---|
GBX 1,675 |
GBX 0 |
GBX 1,624 |
-100% |
---|
Hikma Pharmaceuticals is trading in a bullish trend and several arguments are in favor of the continuation of this trend.
The company’s fundamentals are still strong. Sales progression is encouraging and the group benefits from an interesting profitability with a net margin at 15.5% last year. Analysts from Thomson Reuters consensus keep revising upward their EPS estimates.
Technically, the consolidation phase engaged when touching GBp 1780 has brought the stock back to attractive prices. Moving averages on all time scales are well oriented and suggest a renewed bullish trend for a return towards GBp 1780.
In consequence, investors can take a long position in Hikma Pharmaceuticals with a target price at GBp 1780. This level is the long term resistance. A new bullish fluctuation could lead the security toward its highest level in case of breakout of this resistance. A stop loss will be set under the short term support at GBp 1639.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.